Evidence map›Paper›PMID 26668126›Full record

Trial reportLeukemia2016

Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5).

E Schuler, A Giagounidis, D Haase, K Shirneshan, G Büsche, U Platzbecker, F Nolte, K Götze, R F Schlenk, A Ganser and 10 more

Abstract readClinical Trial, Phase IILetterMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Current treatment algorithm for the management of lower-risk MDS.Hematology. American Society of Hematology. Education Program · 2017
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

E SchulerDepartment for Hematology, Oncology and Clinical Immunology, University Hospital, Heinrich-Heine-University, Duesseldorf, Germany.
A GiagounidisDepartment of Hematology, Oncology and Palliative Care, Marien Hospital Duesseldorf, Duesseldorf, Germany.
D HaaseUniversity Medicine Goettingen, Clinics of Hematology and Medical Oncology, Goettingen, Germany.
K ShirneshanUniversity Medicine Goettingen, Clinics of Hematology and Medical Oncology, Goettingen, Germany.
G BüscheHannover Medical School, Institute of Pathology, Hannover, Germany.
U PlatzbeckerDepartment of Hematology, University Hospital Dresden, Dresden, Germany.
F NolteDepartment of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.
K GötzeDepartment of Internal Medicine, Technical University of Munich, Munich, Germany.
R F SchlenkDepartment of Internal Medicine, University Hospital Ulm, Ulm, Germany.
A GanserDepartment of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
A LetschDepartment of Hematology and Oncology, Charité, Benjamin Franklin University, Berlin, Germany.
F BraulkeUniversity Medicine Goettingen, Clinics of Hematology and Medical Oncology, Goettingen, Germany.
M LübbertUniversity Hospital Freiburg, Internal Medicine, Freiburg, Germany.
G BugDepartment of Internal Medicine, University Hospital Frankfurt, Frankfurt, Germany.
P SchafhausenDepartment of Oncology, Hematology, BMT with section Pneumology, Hubertus Wald Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
U BacherUniversity Medicine Goettingen, Clinics of Hematology and Medical Oncology, Goettingen, Germany.
N GattermannDepartment for Hematology, Oncology and Clinical Immunology, University Hospital, Heinrich-Heine-University, Duesseldorf, Germany.
M WulfertDepartment for Hematology, Oncology and Clinical Immunology, University Hospital, Heinrich-Heine-University, Duesseldorf, Germany.
R HaasDepartment for Hematology, Oncology and Clinical Immunology, University Hospital, Heinrich-Heine-University, Duesseldorf, Germany.
U GermingDepartment for Hematology, Oncology and Clinical Immunology, University Hospital, Heinrich-Heine-University, Duesseldorf, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAged, 80 and overChromosome DeletionChromosomes, Human, Pair 5FemaleHumansImmunologic FactorsKaplan-Meier EstimateLenalidomideMaleMiddle AgedMyelodysplastic SyndromesProportional Hazards ModelsProspective StudiesThalidomideImmunologic FactorsLenalidomideThalidomide

Identifiers

PMID26668126

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.